Исследование однонуклеотидных полиморфизмов генов ABC-транспортеров в опухоли молочной железы: связь с экспрессией
Об авторах
М. М. Цыганов
Томский национальный исследовательский медицинский центр Российской академии наук; Национальный исследовательский Томский государственный университет
Россия
Россия
М. К. Ибрагимова
Томский национальный исследовательский медицинский центр Российской академии наук; Национальный исследовательский Томский государственный университет
Россия
Россия
И. В. Дерюшева
Томский национальный исследовательский медицинский центр Российской академии наук
Россия
Россия
Н. В. Литвяков
Томский национальный исследовательский медицинский центр Российской академии наук; Национальный исследовательский Томский государственный университет
Россия
Россия
Список литературы
1. Wind N, Holen I. Multidrug resistance in breast cancer: from in vitro models to clinical studies. International journal of breast cancer. 2011;2011:1-12.
2. Litviakov NV, Cherdyntseva NV, Tsyganov MM, Denisov EV, Garbukov EY, Merzliakova MK, Volkomorov VV, Vtorushin SV, Zavyalova MV, Slonimskaya EM. Changing the expression vector of multidrug resistance genes is related to neoadjuvant chemotherapy response. Cancer chemotherapy and pharmacology. 2013;71(1):153-163.
3. Litviakov NV. Gradient phenomenon of multidrug resistance gene expression in breast cancer during neoadjuvant chemotherapy is related to disease progression. Siberian journal of oncology. 2013(4):58.
4. Sharma G, Mirza S, Parshad R, Srivastava A, Datta Gupta S, Pandya P, Ralhan R. CpG hypomethylation of< i> MDR1</i> gene in tumor and serum of invasive ductal breast carcinoma patients. Clinical biochemistry. 2010;43(4):373-379.
5. Ma J, Dong C, Ji C. MicroRNA and drug resistance. Cancer gene therapy. 2010;17(8):523-531.
6. Sui H, Fan Z, Li Q. Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells. Journal of International Medical Research. 2012;40(2):426-435.
7. Di Francia R, Siesto R, Valente D, Spart D, Berretta M. Pharmacogenomics panel test for prevention toxicity in patient who receive Fluoropirimidine/Oxaliplatin-based therapy. Eur Rev Med Pharmacol Sci. 2012;16(9):1211-1217.
8. Taheri M, Mahjoubi F, Omranipour R. Effect of MDR1 polymorphism on multidrug resistance expression in breast cancer patients. Genet Mol Res. 2010;9(1):34-40.
9. Schwartz GF, Hortobagyi GN. Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania. The Breast Journal. 2004;10(4):273-294.
10. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic acids research. 2001;29(9):e45-e45.
11. Kim HJ, Im SA, Keam B, Ham HS, Lee KH, Kim TY, Kim YJ, Oh DY, Kim JH, Han W. ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy. Cancer science. 2015;106(1):86-93.
12. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, Kurata Y, Kigawa J, Higuchi S. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. Journal of Pharmacology and Experimental Therapeutics. 2001;297(3):1137-1143.
13. Cizmarikova M, Wagnerova M, Schonova L, Habalova V, Kohut A, Linkova A, Sarissky M, Mojzis J, Mirossay L, Mirossay A. MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. The pharmacogenomics journal. 2010;10(1):62-69.
14. Chen Z, Le H, Zhang Y, Qian L, Sekhar KR, Li W. Lung resistance protein and multidrug resistance protein in non-small cell lung cancer and their clinical significance. Journal of International Medical Research. 2011;39(5):1693-1700.
15. Vulsteke C, Lambrechts D, Dieudonne A, Hatse S, Brouwers B, Van Brussel T, Neven P, Belmans A, Schoffski P, Paridaens R. Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC). Annals of Oncology. 2013;24(6):1513-1525.
16. Kiyotani K, Mushiroda T, Imamura CK, Hosono N, Tsunoda T, Kubo M, Tanigawara Y, Flockhart DA, Desta Z, Skaar TC. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. Journal of Clinical Oncology. 2010;28(8):1287-1293.
17. Brauch H, Murdter TE, Eichelbaum M, Schwab M. Pharmacogenomics of tamoxifen therapy. Clinical chemistry. 2009;55(10):1770-1782.
18. Chen S, Villeneuve L, Jonker D, Couture F, Laverdiere I, Cecchin E, Innocenti F, Toffoli G, Levesque E, Guillemette C. ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients. Pharmacogenetics and Genomics. 2015;25(12): 573-583.
19. Noguchi K, Katayama K, Sugimoto Y. Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics. Pharmacogenomics and personalized medicine. 2014; 7: 53-64.
20. Sun S, Shi W, Wu Z, Zhang G, Yang B, Jiao S. Prognostic significance of the mRNA expression of ERCC1, RRM1, TUBB3 and TYMS genes in patients with non-small cell lung cancer. Experimental and therapeutic medicine. 2015;10(3):937-941.
Рецензия
Для цитирования:
Цыганов М.М., Ибрагимова М.К., Дерюшева И.В., Литвяков Н.В. Исследование однонуклеотидных полиморфизмов генов ABC-транспортеров в опухоли молочной железы: связь с экспрессией. Медицинская генетика. 2017;16(1):25-30.
For citation:
Tsyganov M.M., Ibragimova M.K., Deryusheva I.V., Litviakov N.V. The study single nucleotide polymorphisms ABC-transporter genes in breast cancer: correlation with expression. Medical Genetics. 2017;16(1):25-30. (In Russ.)
Просмотров: 521
Послать статью по эл. почте 